Literature DB >> 25174401

A novel role for Plk4 in regulating cell spreading and motility.

C O Rosario1, K Kazazian2, F S W Zih2, O Brashavitskaya1, Y Haffani3, R S Z Xu4, A George3, J W Dennis5, C J Swallow6.   

Abstract

Polo family kinase 4 (Plk4) is required for mitotic progression, and is haploinsufficient for tumor suppression and timely hepatocyte polarization in regenerating liver. At the same time, recent evidence suggests that Plk4 expression may have a role in clinical cancer progression, although the mechanisms are not clear. Here we identify a gene expression pattern predictive of reduced motility in Plk4(+/-) murine embryonic fibroblasts (MEFs) and validate this prediction with functional assays of cell spreading, migration and invasion. Increased Plk4 expression enhances cell spreading in Plk4(+/-) MEFs and migration in human embryonic kidney 293T cells, and increases invasion by DLD-1 colon cancer cells. Plk4 depletion impairs invasion of wild-type MEFs and suppresses invasion by MDA-MB231 breast cancer cells. Cytoskeletal reorganization and development of polarity are impaired in Plk4-deficient cells that have been stimulated to migrate. Endogenous Plk4 phosphorylated at the autophosphorylation site S305 localizes to the protrusions of motile cells, coincident with the RhoA GEF Ect2, GTP-bound RhoA and the RhoA effector mDia. Taken together, our findings reveal an unexpected activity of Plk4 that promotes cell migration and may underlie an association between increased Plk4 expression, cancer progression and death from metastasis in solid tumor patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25174401     DOI: 10.1038/onc.2014.275

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  Late mitotic failure in mice lacking Sak, a polo-like kinase.

Authors:  J W Hudson; A Kozarova; P Cheung; J C Macmillan; C J Swallow; J C Cross; J W Dennis
Journal:  Curr Biol       Date:  2001-03-20       Impact factor: 10.834

2.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

Authors:  Gennadi V Glinsky; Olga Berezovska; Anna B Glinskii
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

3.  The Polo kinase Plk4 functions in centriole duplication.

Authors:  Robert Habedanck; York-Dieter Stierhof; Christopher J Wilkinson; Erich A Nigg
Journal:  Nat Cell Biol       Date:  2005-11       Impact factor: 28.824

4.  Purification and characterization of beta-actin-rich tumor cell pseudopodia: role of glycolysis.

Authors:  T N Nguyen; H J Wang; S Zalzal; A Nanci; I R Nabi
Journal:  Exp Cell Res       Date:  2000-07-10       Impact factor: 3.905

5.  Plk4 trans-autophosphorylation regulates centriole number by controlling betaTrCP-mediated degradation.

Authors:  Gernot Guderian; Jens Westendorf; Andreas Uldschmid; Erich A Nigg
Journal:  J Cell Sci       Date:  2010-06-01       Impact factor: 5.285

6.  The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4.

Authors:  Inês Cunha-Ferreira; Ana Rodrigues-Martins; Inês Bento; Maria Riparbelli; Wei Zhang; Ernest Laue; Giuliano Callaini; David M Glover; Mónica Bettencourt-Dias
Journal:  Curr Biol       Date:  2008-12-11       Impact factor: 10.834

7.  The structure of the plk4 cryptic polo box reveals two tandem polo boxes required for centriole duplication.

Authors:  Lauren K Slevin; Jonathan Nye; Derek C Pinkerton; Daniel W Buster; Gregory C Rogers; Kevin C Slep
Journal:  Structure       Date:  2012-09-20       Impact factor: 5.006

8.  Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis.

Authors:  Andrew J Holland; Daniele Fachinetti; Sandrine Da Cruz; Quan Zhu; Benjamin Vitre; Mariana Lince-Faria; Denaly Chen; Nicole Parish; Inder M Verma; Monica Bettencourt-Dias; Don W Cleveland
Journal:  Mol Biol Cell       Date:  2012-03-28       Impact factor: 4.138

9.  Autophosphorylation of polo-like kinase 4 and its role in centriole duplication.

Authors:  James E Sillibourne; Frederik Tack; Nele Vloemans; An Boeckx; Sathiesan Thambirajah; Pascal Bonnet; Frans C S Ramaekers; Michel Bornens; Thierry Grand-Perret
Journal:  Mol Biol Cell       Date:  2009-12-23       Impact factor: 4.138

10.  PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility.

Authors:  Yangmi Lim; Ssang-Taek Lim; Alok Tomar; Margaret Gardel; Joie A Bernard-Trifilo; Xiao Lei Chen; Sean A Uryu; Rafaela Canete-Soler; Jinbin Zhai; Hong Lin; William W Schlaepfer; Perihan Nalbant; Gary Bokoch; Dusko Ilic; Clare Waterman-Storer; David D Schlaepfer
Journal:  J Cell Biol       Date:  2008-01-14       Impact factor: 10.539

View more
  21 in total

Review 1.  The Emerging Link between Centrosome Aberrations and Metastasis.

Authors:  Gina M LoMastro; Andrew J Holland
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

2.  Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals.

Authors:  Michelle S Levine; Bjorn Bakker; Bram Boeckx; Julia Moyett; James Lu; Benjamin Vitre; Diana C Spierings; Peter M Lansdorp; Don W Cleveland; Diether Lambrechts; Floris Foijer; Andrew J Holland
Journal:  Dev Cell       Date:  2017-01-26       Impact factor: 12.270

3.  Downregulation of PLK4 expression induces apoptosis and G0/G1-phase cell cycle arrest in keloid fibroblasts.

Authors:  Ru-Lin Huang; Chuanqi Liu; Rao Fu; Yuxin Yan; Jing Yang; Xinggang Wang; Qingfeng Li
Journal:  Cell Prolif       Date:  2022-06-07       Impact factor: 8.755

Review 4.  Centrosome amplification: a suspect in breast cancer and racial disparities.

Authors:  Angela Ogden; Padmashree C G Rida; Ritu Aneja
Journal:  Endocr Relat Cancer       Date:  2017-05-17       Impact factor: 5.678

Review 5.  PLK4: a promising target for cancer therapy.

Authors:  Yi Zhao; Xin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-06       Impact factor: 4.553

6.  Direct interaction between CEP85 and STIL mediates PLK4-driven directed cell migration.

Authors:  Yi Liu; Jaeyoun Kim; Reuben Philip; Vaishali Sridhar; Megha Chandrashekhar; Jason Moffat; Mark van Breugel; Laurence Pelletier
Journal:  J Cell Sci       Date:  2020-04-23       Impact factor: 5.285

7.  Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy.

Authors:  Zhenhua Li; Kun Dai; Chijuan Wang; Yawen Song; Feng Gu; Fangfang Liu; Li Fu
Journal:  J Cancer       Date:  2016-06-06       Impact factor: 4.207

8.  Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.

Authors:  Dominic P Byrne; Christopher J Clarke; Philip J Brownridge; Anton Kalyuzhnyy; Simon Perkins; Amy Campbell; David Mason; Andrew R Jones; Patrick A Eyers; Claire E Eyers
Journal:  Biochem J       Date:  2020-07-17       Impact factor: 3.857

9.  Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex.

Authors:  Hideaki Ito; Takumi Tsunoda; Miho Riku; Shingo Inaguma; Akihito Inoko; Hideki Murakami; Hiroshi Ikeda; Michiyuki Matsuda; Kenji Kasai
Journal:  Oncogene       Date:  2019-11-21       Impact factor: 9.867

10.  Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.

Authors:  Simone Treiger Sredni; Anders W Bailey; Amreena Suri; Rintaro Hashizume; Xingyao He; Nundia Louis; Tufan Gokirmak; David R Piper; Daniel M Watterson; Tadanori Tomita
Journal:  Oncotarget       Date:  2017-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.